Optimisation of antiepileptic drug therapy. The importance of serum drug concentration monitoring

Clinical Pharmacokinetics

Volumn 31, Issue 2, 1996, Pages 120-130

  Yukawa, Eiji ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLONAZEPAM; ETHOSUXIMIDE; PHENOBARBITAL; PHENYTOIN; VALPROIC ACID;

AGE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; EPILEPSY; FEEDBACK SYSTEM; HUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; SEIZURE;

EID: 0029945297     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199631020-00004     Document Type: Review

References (102)

1. Tozer TN, Winter ME. Phenytoin. In: Evans WE, Schentag JJ, Jusko WJ, editors. Applied pharmacokinetics: principles of therapeutic drug monitoring. 3rd ed. San Francisco: Applied Therapeutics, 1992: 1-44
2. Bowdle TA, Patel IH, Levy RH, et al. Valproic acid dosage and plasma protein binding and clearance. Clin Pharmacol Ther 1980; 28: 486-92
3. Kumps AH. Dose-dependency of the ratio between carbamazepine serum levels and dosage in patients with epilepsy. Ther Drug Monit 1981; 3: 271-4
4. Thomson AH, Brodie MJ. Pharmacokinetic optimisation of anticonvulsant therapy. Clin Pharmacokinet 1942; 23: 216-30
5. Brodie MJ, Feely J. Practical clinical pharmacology. Therapeutic drug monitoring and clinical trials. BMJ 1988; 296: 1110-4
6. Larkin JG, Herrick AL, McGuire GM, et al. Antiepileptic drug monitoring at the epilepsy clinic: a prospective evaluation. Epilepsia 1991; 32: 89-95
7. Nelson E, Powell JR, Conrad K, et al. Phenobarbital pharmacokinetics and bioavailability in adults. J Clin Pharmacol 1982; 22: 141-8
8. Welinsky AJ, Freil PN, Levy RH, et al. Kinetics of phenobarbital in normal subjects and epileptic patients. Eur J Clin Pharmacol 1982; 23: 87-92
9. Battino D, Estienne M, Avanzini G. Clinical pharmacokinetics of antiepileptic drug in paediatric patients. Part I: phenobarbital, primidone, valproic acid, ethosuximide and mesuximide. Clin Pharmacokinet 1995; 29: 257-86
10. Heimann G, Galdtke E. Pharmacokinetics of phenobarbital in childhood. Eur J Clin Pharmacol 1977; 12: 305-10
11. Browne TR, Von Langenhove A, Castello CE, et al. Pharmacokinetic equivalence of stable-isotope-labeled and unlabeled drugs. Phenobarbital in man. J Clin Pharmacol 1982; 12: 309-15
12. Dodson WE, Rust Jr RS. Phenobarbital: absorption, distribution, and excretion, In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995: 379-87
13. Guelen PJM, Van Der Kleijn E, Woudstra U. Statistical analysis of pharmacokinetic parameters in epileptic patients chronically treated with antiepileptic drugs. In: Schneider H, Janz D, Gardner-Thorpe C, et al., editors. Clinical pharmacology of antiepileptic drugs. Berlin: Springer-Verlag, 1975: 2-10
14. Yukawa E, Higuchi S, Aoyama T. Phenobarbitone population pharmacokinetics from routine clinical data: role of patient characteristics for estimating dosing regimens. J Pharm Pharmacol 1992; 44: 755-60
15. Martin PR, Kapur BM, Whiteside EA, et al. Intravenous phenobarbital therapy in barbiturate and other hypnosedative withdrawal reactions: a kinetic approach. Clin Pharmacol Ther 1979; 26: 256-64
16. Fischer JH, Lockman LA, Zaske D, et al. Phenobarbital maintenance dose requirements in treating neonatal seizures. Neurology 1981; 31: 1042-4
17. Minagawa K, Miura K, Chiba K, et al. Pharmacokinetics and relative bioavailability of intramuscular phenobarbital sodium or acid in infants. Pediatr Pharmacol 1981; 1: 279-89
18. Painter MJ, Gaus LM. Phenobarbital: clinical use. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995: 401-7
19. Hooper WD, Bochner F, Eadie MJ, et al. Plasma protein binding of diphenylhydantoin: effects of sex hormones, renal and hepatic disease. Clin Pharmacol Ther 1974; 15: 276-82
20. Lunde PKM, Rane A, Yaffe SJ, et al. Plasma protein binding of diphenylhydantoin in man: interaction with other drugs and the effect of temperature and plasma dilution. Clin Pharmcol Ther 1970; 11: 846-55
21. Hvidberg EF, Dam M. Clinical pharmacokinetics of anticonvulsants. Clin Pharmacokinet 1976; 1: 161-88
22. Bochner F, Hooper WD, Sutherland JM, et al. The renal handling of dihenylhydantoin and 5-(p-hydroxyphenyl)-5-phenylhydantoin. Clin Pharmacol Ther 1973; 14: 791-6
23. Edeki TI, Brase DA. Phenytoin disposition and toxicity: Role of pharmacogenetic and interethnic factors. Drug Metab Rev 1995; 27: 449-69
24. Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm 1980; 8: 553-71
25. Grasela TH, Sheiner LB, Rambeck B, et al. Steady-state pharmacokinetics of phenytoin from routinely collected patient data. Clin Pharmacokinet 1983; 8: 355-64
26. Miller R, Rheeders M, Klein C, et al. Population pharmacokinetics of phenytoin in South African black patients. S Afr Med J 1987; 72: 188-90
27. Chan E, Ti TY, Lee HS. Population pharmacokinetics of phenytoin in Singapore Chinese. Eur J Clin Pharmacol 1990; 39: 177-81
28. Hori R, Okumura K, Kitazawa S, et al. Estimation of population pharmacokinetic parameters in Japanese patients. III. Phenytoin [in Japanese]. Yakuzaigaku 1990; 50: 292-9
29. Yukawa E, Higuchi S, Aoyama T. Population pharmacokinetics of phenytoin from routine clinical data in Japan: an update. Chem Pharm Bull 1990; 38: 1973-6
30. Bauer LA, Blouin RA. Phenytoin Michaelis-Menten pharmacokinetics in Caucasian paediatric patients. Clin Pharmacokinet 1983; 8: 545-9
31. Graves NM, Leppik IE, Termond E, et al. Phenytoin clearances in a compliant population: description and application. Ther Drug Monit 1986; 8: 427-33
32. Yukawa E, Higuchi S, Aoyama T. Phenytoin dosage adjustment method using population clearance. Chem Pharm Bull 1990; 38: 510-2
33. Morselli PL. Carbamazepine: absorption, distribution, and excretion, In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995: 515-28
34. Riad LE, Chan KKH, Wagner Jr WE, et al. Simultaneous first-and zero-order absorption of carbamazepine tablets in humans. J Pharm Sci 1986; 75: 897-900
35. Sanchez A, Duran JA, Serrano JS. Steady-state carbamazepine plasma concentration-dose ratios in epileptic patients. Clin Pharmacokinet 1986; 11: 411-4
36. Bertilsson L. Clinical pharmacokinetics of carbamazepine. Clin Pharmacokinet 1978; 3: 128-43
37. Hori R, Okumura K, Kitazawa S, et al. Estimation of population pharmacokinetic parameters in Japanese patients. II. Carbamazepine [in Japanese]. Yakuzaigaku 1989; 49: 304-12
38. Battino D, Estienne M, Avanzini G. Clinical pharmacokinetics of antiepileptic drug in paediatric patients. Part II: phenytoin, carbamazepine, sulthiame, lamotrigine, vigabatrin, oxcarbazepine and felbamate. Clin Pharmacokinet 1995; 29: 341-69
39. Sumi M, Watari N, Umezawa O, et al. Pharmacokinetic study of carbamazepine and its epoxide metabolite in humans. J Pharmacobiodynamics 1987; 10: 652-61
40. Mikati MA, Browne TR, Collins JF, et al. Time course of carbamazepine autoinduction. Neurology 1989; 39: 592-4
41. Bertilsson L, Tomson T, Tybring G. Pharmacokinetics: time-dependent changes (autoinduction of carbamazepine epoxidation). J Clin Pharmacol 1986; 26: 459-62
42. Cotter LM, Eadie MJ, Hooper WD, et al. The pharmacokinetics of carbamazepine. Eur J Clin Pharmacol 1977; 12: 451-6
43. Eichelbaum M, Kothe KW, Hoffman F, et al. Kinetics and metabolism of carbamazepine during combined antiepileptic drug therapy. Clin Pharmcol Ther 1979; 26: 366-71
44. Summers B, Summers RS. Carbamazepine clearance in paediatric epilepsy patients: influence of body mass, dose, sex and co-medication. Clin Pharmacokinet 1989; 17: 208-16
45. Battino D, Bossi L, Croci D, et al. Carbamazepine plasma levels in children and adults: influence of age, dose, and associated therapy. Ther Drug Monit 1980; 2: 315-22
46. Christiansen J, Dam M. Influence of phenobarbital and diphenylhydantoin on plasma carbamazepine levels in patients with epilepsy. Acta Neurol Scand 1973; 49: 543-6
47. Baciewicz AM. Carbamazepine drug interactions. Ther Drug Monit 1986; 8: 305-17
48. Eichelbaum M, Ekbom K, Bertilsson L, et al. Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses. Eur J Clin Pharmacol 1975; 8: 337-41
49. Eichelbaum M, Kothe KW, Hoffman F, et al. Use of stable labelled carbamazepine to study its kinetics during chronic carbamazepine treatment. Eur J Clin Pharmacol 1982; 23: 241-4
50. Choonara IA, Rane A. Therapeutic drug monitoring of anticonvulsants: state of the art. Clin Pharmacokinet 1990; 18: 318-28
51. Levy RH, Shen DD. Valproic acid: absorption, distribution, and excretion, In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995: 605-19
52. Ohdo S, Nakano S, Ogawa N. Circadian changes of valproate kinetics depending on meal condition in humans. J Clin Pharmacol 1992; 32: 822-6
53. Zaccara G, Messori A, Moroni F. Clinical pharmacokinetics of valproic acid: 1988. Clin Pharmacokinet 1988; 15: 367-89
54. Hori R, Okumura K, Kitazawa S, et al. Estimation of population pharmacokinetic parameters in Japanese patients: I. Valproic acid [in Japanese]. Yakuzaigaku 1989; 49: 148-56
55. Kodama Y, Koike Y, Kimoto H, et al. Binding parameters of valproic acid to serum protein in healthy adults at steady state. Ther Drug Monit 1992; 14: 50-60
56. Chiba K, Suganuma T, Ishizaki T, et al. Comparison of steady-state pharmacokinetics of valproic acid in children between monotherapy and multiple antiepileptic drug treatment. J Pediatr 1985; 106: 653-8
57. Hall K, Otten N, Johnston B, et al. A multivariable analysis of factors governing the steady-state pharmacokinetics of valproic acid in 52 young epileptics. J Clin Pharmacol 1985; 25: 261-8
58. Cloyd JC, Fisher JH, Kriel RL, et al. Valproic acid pharmacokinetics in children: IV. Effects of age and antiepileptic drugs on protein binding and intrinsic clearance. Clin Pharmacol Ther 1993; 53: 22-9
59. Schappel GJ, Beran RG, Doecke CJ, et al. Pharmacokinetics of sodium valproate in epileptic patients: prediction of maintenance dosage by single-dose study. Eur J Clin Pharmacol 1980; 17: 71-7
60. Perucca E, Gatti G, Frigo GM, et al. Disposition of sodium valproate in epileptic patients. Br J Clin Pharmacol 1978; 5: 495-9
61. Gugler R, Schell A, Eichelbaum M, et al. Disposition of valproic acid in man. Eur J Clin Pharmacol 1977; 12: 125-32
62. Bowdle TA, Patel IH, Levy RH, et al. Valproic acid dosage and plasma protein binding and clearance. Clin Pharmacol Ther 1980; 28: 486-92
63. Klotz U, Antonin KH. Pharmacokinetics and bioavailability of sodium valproate. Clin Pharmacol Ther 1977; 21: 736-43
64. Cloyd JC, Kriel RL, Fisher JH, et al. Pharmacokinetics of valproic acid in children: I. Multiple antiepileptic drug therapy. Neurology 1983; 33: 185-91
65. Guger R, von Unruh GE. Clinical pharmacokinetics of valproic acid. Clin Pharmacokinet 1980; 5: 67-83
66. Buchanan RA, Fernandey L, Kinkel AW. Absorption and elimination of ethosuximide in children. J Clin Pharmacol 1969; 9: 393-8
67. Buchanan RA, Kinkel AW, Smith TC. The absorption and excretion of ethosuximide. Int J Clin Pharmacol Ther Toxicol 1973; 7: 213-8
68. Bauer LA, Harris C, Wilensky AJ, et al. Ethosuximide kinetics: possible interaction with valproic acid. Clin Pharmacol Ther 1982; 31: 741-5
69. Sherwin AL. Ethosuximide: clinical use. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995: 667-73
70. Greenblatt DJ, Miller LG, Shader RI. Clonazepam pharmacokinetics, brain uptake, and receptor interactions. J Clin Psychiatry 1987; 48 Suppl.: 4-11
71. Eadie MJ, Tyrer JM, Smith GA, et al. Pharmacokinetics of drugs used for petit mal 'absence' epilepsy. Clin Exp Neurol 1977; 14: 172-83
72. Lockman LA, Kriel R, Zaske D, et al. Phenobarbital dosage for control of neonatal seizures. Neurology 1979; 29: 1445-9
73. Yukawa E, Higuchi S, Aoyama T. Influence of age and co-medication on steady-state phenobarbital serum level-dose ratios in Japanese paediatric patients. J Clin Pharm Ther 1992; 17: 249-53
74. Levine M, Chang T. Therapeutic drug monitoring of phenytoin: rationale and current status. Clin Pharmacokinet 1990; 19: 341-58
75. Chiba K, Ishizaki T, Miura H, et al. Michaelis-Menten pharmacokinetics of diphenylhydantoin and application in the pediatric age patient. J Pediatr 1980; 96: 479-84
76. Richens A, Dunlop A. Phenytoin dosage nomogram. Lancet 1975; 11: 1305-6
77. Rambeck B, Boenigk HE, Dunlop A, et al. Predicting phenytoin dose: a revised nomogram. Ther Drug Monit 1982; 1: 325-33
78. Wagner JG. New and simple method to predict dosage of drugs obeying simple Michaelis-Menten elimination kinetics and to distinguish such kinetics from simple first order and from parallel Michaelis-Menten and first order kinetics. Ther Drug Monit 1985; 7: 377-86
79. Bryson SM, Ai-Lanqawi Y, Kelman AW, et al. Comparison of a Bayesian forecasting technique with a new method for estimating phenytoin dose requirements. Ther Drug Monit 1988; 10: 80-4
80. Yukawa E, Higuchi S, Aoyama T. Clinical utility of a new and simple technique for individualizing phenytoin dosage. J Pharmacobiodynamics 1989; 12: 187-92
81. Burton ME, Vasco MR, Brater DC. Comparison of drug dosing methods. Clin Pharmacokinet 1985; 10: 1-37
82. Toscano JP, Jameson JP. Comparison of four single-point phenytoin dosage prediction techniques using computer-simulated pharmacokinetic values. Clin Pharm 1986; 5: 396-402
83. Vozeh S, Muir KT, Sheiner LB, et al. Predicting individual phenytoin dosage. J Pharmacokinet Biopharm 1981; 9: 131-46
84. Yuen GJ, Taylor JW, Ludden TM, et al. Predicting phenytoin dosages using Bayesian feedback: a comparison with other methods. Ther Drug Monit 1983; 5: 437-41
85. Yuen GJ, Latimer PT, Littlefield LC, et al. Phenytoin dosage predictions in paediatric patients. Clin Pharmacokinet 1989; 16: 254-60
86. Yukawa E, Higuchi S, Ohtsubo K, et al. Comparison of single-point phenytoin dosage prediction techniques. J Clin Pharm Ther 1988; 13: 293-305
87. Yukawa E, Higuchi S, Aoyama T. Evaluation of single-point phenytoin dosage prediction methods in paediatric patients. J Pharmacobiodynamics 1988; 11: 736-43
88. Zaccara G, Messori A, Muscas GC, et al. Predictive performance of pharmacokinetic methods for phenytoin dosing: a multi-center evaluation in 282 patients with epilepsy. Epilep Res 1989; 3: 253-61
89. Pryka RD, Rodvold KA, Erdman SM. An updated comparison of drug dosing methods. Part 1: Phenytoin. Clin Pharmacokinet 1991; 20: 209-17
90. Macphee GJA, Brodie MJ. Carbamazepine substitution in severe partial epilepsy: implication of autoinduction of metabolism. Postgrad Med J 1985; 61: 779-83
91. Eichelbaum M, Tomson T, Tybring G, et al. Carbamazepine metabolism in man: induction and pharmacogenetic aspects. Clin Pharmacokinet 1985; 10: 80-90
92. Macphee GJA, Butler E, Brodie MJ. Intradose and circadian variation in circulating carbamazepine and its epoxide in epileptic patients: a consequence of autoinduction of metabolism. Epilepsia 1987; 28: 286-94
93. Levy RH, Kerr BM. Clinical pharmacokinetics of carbamazepine. J Clin Psychiatry 1988; 49 Suppl. 4: 58-62
94. Yukawa E, Suzuki A, Higuchi S, et al. Influence of age and co-medication on steady-state carbamazepine serum level-dose ratios in Japanese paediatric patients. J Clin Pharm Ther 1992; 17: 65-9
95. Rylance GW, Moreland TA, Butcher GM. Carbamazepine dose-frequency requirements in children. Arch Dis Child 1979; 54: 454-8
96. Rapeport WG, McInnes GT, Thompson GG, et al. Hepatic enzyme induction and leucocyte delta-aminolaevulinic acid synthase activity: studies with carbamazepine. Br J Clin Pharmacol 1983; 16: 133-7
97. Garcia MJ, Alonso AC, Maza A, et al. Comparison of methods of carbamazepine dosage, individualization in epileptic patients. J Clin Pharm Ther 1988; 13: 375-80
98. Rambeck B, May T, Juergens U. Serum concentrations of carbamazepine and its epoxide and diol metabolites in epileptic patients: the influence of dose and co-medication. Ther Drug Monit 1987; 9: 298-303
99. Rowan AJ, Binnie CD, Warfield CA, et al. The delayed effect of sodium valproate on the photoconvulsive response in man. Epilepsia 1979; 20: 61-8
100. Yukawa E, Suzuki A, Higuchi S, et al. Influence of age and concurrent medication on steady-state valproic acid serum level-dose ratios in Japanese paediatric patients. J Clin Pharm Ther 1991; 16: 291-7
101. Haerer AK, Buchanan RA, Wiygul FM. Ethosuximide blood levels in epileptics. J Clin Pharmacol 1970; 10: 370-4
102. Eadie MJ. Plasma level monitoring of anticonvulsants. Clin Pharmacokinet 1976; 1: 52-66